At its annual R&D investor briefing, CSL demonstrates how its growing, innovative pipeline is well-positioned to meet the current and future needs of patients and public health. Among the highlights:
Top-line Phase III results for garadacimab (CSL312, anti-FXIIa), an investigational first-in-class monoclonal antibody being developed as a long-term preventive treatment for patients with HAE, demonstrated that the study met its primary and secondary efficacy objectives and showed favorable safety and tolerability. CSL aims to begin filing for approval with global regulatory authorities next calendar year. Garadacimab was discovered and optimized by scientists at CSL’s Bio21–based Research site, with formulation and manufacturing for the clinical programs completed at the CSL Broadmeadows Biotech Manufacturing Facility.
(Source: CSL Behring)
